DSM-Firmenich 미래 성장

Future 기준 확인 3/6

DSM-Firmenich (는) 각각 연간 43.7% 및 4.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 43.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 5.4% 로 예상됩니다.

주요 정보

43.7%

수익 성장률

43.8%

EPS 성장률

Chemicals 수익 성장	20.0%
매출 성장률	4.3%
향후 자기자본 수익률	5.4%
애널리스트 커버리지	Good
마지막 업데이트	18 Nov 2024

최근 미래 성장 업데이트

Recent updates

We Think DSM-Firmenich (AMS:DSFIR) Has A Fair Chunk Of Debt

Oct 20

DSM-Firmenich AG's (AMS:DSFIR) Popularity With Investors Is Under Threat From Overpricing

Sep 23

DSM-Firmenich AG (AMS:DSFIR) Shares Could Be 31% Below Their Intrinsic Value Estimate

Feb 18

DSM-Firmenich AG's (AMS:DSFIR) Share Price Could Signal Some Risk

Dec 24

Are Investors Undervaluing DSM-Firmenich AG (AMS:DSFIR) By 23%?

Nov 19

Getting In Cheap On DSM-Firmenich AG (AMS:DSFIR) Is Unlikely

Sep 10

수익 및 매출 성장 예측

ENXTAM:DSFIR - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	13,821	953	1,094	1,992	18
12/31/2025	13,360	806	973	1,916	20
12/31/2024	12,818	471	839	1,706	20
6/30/2024	12,455	-190	745	1,452	N/A
3/31/2024	11,541	-424	659	1,359	N/A
12/31/2023	10,627	-658	573	1,265	N/A
9/30/2023	9,686	-456	434	1,112	N/A
6/30/2023	8,745	-254	287	959	N/A
3/31/2023	8,568	100	301	962	N/A
12/31/2022	8,390	454	314	965	N/A
9/30/2022	9,582	837	412	1,056	N/A
6/30/2022	7,867	823	510	1,147	N/A
3/31/2022	7,568	822	680	1,287	N/A
12/31/2021	7,269	820	850	1,427	N/A
9/30/2021	7,955	660	884	1,507	N/A
6/30/2021	7,558	493	906	1,489	N/A
3/31/2021	7,572	423	906	1,497	N/A
12/31/2020	8,106	448	868	1,494	N/A
9/30/2020	7,960	510	809	1,434	N/A
6/30/2020	8,034	557	810	1,462	N/A
3/31/2020	9,011	722	826	1,471	N/A
12/31/2019	7,998	675	744	1,385	N/A
9/30/2019	8,272	820	766	1,399	N/A
6/30/2019	8,502	794	747	1,395	N/A
3/31/2019	9,124	934	612	1,282	N/A
12/31/2018	9,267	1,069	698	1,391	N/A
9/30/2018	9,235	984	657	1,310	N/A
6/30/2018	9,106	2,082	550	1,170	N/A
3/31/2018	8,908	1,942	N/A	1,110	N/A
12/31/2017	8,632	1,761	N/A	996	N/A
9/30/2017	8,471	1,676	N/A	993	N/A
6/30/2017	8,333	738	N/A	1,028	N/A
3/31/2017	8,166	711	N/A	1,077	N/A
12/31/2016	7,920	645	N/A	1,018	N/A
9/30/2016	7,831	588	N/A	958	N/A
6/30/2016	7,778	274	N/A	914	N/A
3/31/2016	7,749	214	N/A	811	N/A
12/31/2015	7,722	174	N/A	696	N/A
9/30/2015	7,607	66	N/A	800	N/A
6/30/2015	7,456	114	N/A	820	N/A
3/31/2015	7,245	115	N/A	867	N/A
12/31/2014	7,051	123	N/A	808	N/A
9/30/2014	7,415	112	N/A	866	N/A
6/30/2014	7,834	138	N/A	885	N/A
3/31/2014	8,362	182	N/A	1,010	N/A
12/31/2013	8,858	252	N/A	998	N/A

애널리스트 미래 성장 예측

수입 대 저축률: DSFIR 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 1.2% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: DSFIR (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: DSFIR 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: DSFIR 의 수익(연간 4.3% ) Dutch 시장( 8.7% 보다 느리게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: DSFIR 의 수익(연간 4.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: DSFIR 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 5.4 %).

DSM-Firmenich 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates increase by 37%

Consensus EPS estimates increase by 24%, revenue downgraded

Consensus EPS estimates increase by 73%, revenue downgraded

Consensus EPS estimates fall by 19%

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 13%

Recent updates

DSM-Firmenich AG, Annual General Meeting, May 06, 2025

We Think DSM-Firmenich (AMS:DSFIR) Has A Fair Chunk Of Debt

Lesaffre et Compagnie, SA completed the acquisition of Yeast Extract Business of DSM-Firmenich.

KD Pharma Group SA completed the acquisition of MEG-3® fish oil business of dsm-firmenich from DSM-Firmenich AG (ENXTAM:DSFIR).

DSM-Firmenich AG's (AMS:DSFIR) Popularity With Investors Is Under Threat From Overpricing

A Look At The Intrinsic Value Of DSM-Firmenich AG (AMS:DSFIR)

First half 2024 earnings released: EPS: €0.16 (vs €2.12 loss in 1H 2023)

DSM-Firmenich AG to Report Fiscal Year 2024 Results on Feb 13, 2025

DSM-Firmenich AG's (AMS:DSFIR) Shareholders Might Be Looking For Exit

Calculating The Intrinsic Value Of DSM-Firmenich AG (AMS:DSFIR)

Dsm-Firmenich Ag Approves Retirement of Pradeep Pant from the Board

Here's Why DSM-Firmenich (AMS:DSFIR) Can Afford Some Debt

Jingjiang Cosfocus Health Technology Co., Ltd. acquired DSM Jiangshan Pharmaceutical (Jiangsu) Co., Ltd from DSM-Firmenich AG (ENXTAM:DSFIR).

DSM-Firmenich AG (AMS:DSFIR) Shares Could Be 31% Below Their Intrinsic Value Estimate

Full year 2023 earnings: EPS and revenues exceed analyst expectations

DSM-Firmenich AG Proposes Dividend for the Financial Year 2023

DSM-Firmenich AG Proposes Dividend for the Financial Year 2023

DSM-Firmenich AG to Report First Half, 2024 Results on Jul 30, 2024

DSM-Firmenich Makes Voluntary Cash Offer for DSM Shares

DSM-Firmenich AG's (AMS:DSFIR) Share Price Could Signal Some Risk

Now 20% undervalued

Are Investors Undervaluing DSM-Firmenich AG (AMS:DSFIR) By 23%?

DSM-Firmenich AG, Annual General Meeting, May 07, 2024

dsm-firmenich Achieves Regulatory Clearance in China for Two HMO Ingredients for Early Life Nutrition

Getting In Cheap On DSM-Firmenich AG (AMS:DSFIR) Is Unlikely

Consensus EPS estimates increase by 37%

Consensus EPS estimates increase by 24%, revenue downgraded

Consensus EPS estimates increase by 73%, revenue downgraded

DSM-Firmenich AG to Report Fiscal Year 2023 Results on Feb 15, 2024

Consensus EPS estimates fall by 19%

Consensus EPS estimates fall by 12%

DSM-Firmenich AG (ENXTAM:DSFIR) acquired Adare BIOME from Adare Pharmaceuticals, Inc. for enterprise value of €280 million.

Consensus EPS estimates fall by 13%

DSM-Firmenich AG has completed a Follow-on Equity Offering in the amount of €733.264232 million.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견